{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gilbert&page=32&state=Arizona",
    "query": {
      "state": "Arizona",
      "city": "Gilbert",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 991,
    "total_pages": 100,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gilbert&page=33&state=Arizona&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Gilbert&page=31&state=Arizona&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T01:41:08.128Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06532279",
      "title": "Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8",
        "Head and Neck Squamous Cell Carcinoma",
        "Hypopharyngeal Squamous Cell Carcinoma",
        "Laryngeal Squamous Cell Carcinoma",
        "Nasopharyngeal Squamous Cell Carcinoma",
        "Oral Cavity Squamous Cell Carcinoma",
        "Oropharyngeal Squamous Cell Carcinoma",
        "Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage 0 Hypopharyngeal Carcinoma AJCC v8",
        "Stage 0 Nasopharyngeal Carcinoma AJCC v8",
        "Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage I Hypopharyngeal Carcinoma AJCC v8",
        "Stage I Laryngeal Cancer AJCC v8",
        "Stage I Lip and Oral Cavity Cancer AJCC v8",
        "Stage I Nasopharyngeal Carcinoma AJCC v8",
        "Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage II Hypopharyngeal Carcinoma AJCC v8",
        "Stage II Laryngeal Cancer AJCC v8",
        "Stage II Lip and Oral Cavity Cancer AJCC v8",
        "Stage II Nasopharyngeal Carcinoma AJCC v8",
        "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8",
        "Stage III Hypopharyngeal Carcinoma AJCC v8",
        "Stage III Laryngeal Cancer AJCC v8",
        "Stage III Lip and Oral Cavity Cancer AJCC v8",
        "Stage III Nasopharyngeal Carcinoma AJCC v8",
        "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVA Hypopharyngeal Carcinoma AJCC v8",
        "Stage IVA Laryngeal Cancer AJCC v8",
        "Stage IVA Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVA Nasopharyngeal Carcinoma AJCC v8",
        "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stage IVB Hypopharyngeal Carcinoma AJCC v8",
        "Stage IVB Laryngeal Cancer AJCC v8",
        "Stage IVB Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8",
        "Stomatitis"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Image Guided Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "MnSOD Mimetic BMX-001",
          "type": "DRUG"
        },
        {
          "name": "Placebo Administration",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "NRG Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2025-06-23",
      "completion_date": "2032-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 153,
      "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Surprise",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06532279"
    },
    {
      "nct_id": "NCT06750094",
      "title": "A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Amivantamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin calcium/Levoleucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2024-12-12",
      "completion_date": "2029-04-13",
      "has_results": false,
      "last_update_posted_date": "2026-11-03",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 71,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Prescott, Arizona + 60 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Prescott",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06750094"
    },
    {
      "nct_id": "NCT02137837",
      "title": "S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Placebo - Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 37,
      "start_date": "2014-05",
      "completion_date": "2019-12-31",
      "has_results": true,
      "last_update_posted_date": "2021-01-28",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 223,
      "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02137837"
    },
    {
      "nct_id": "NCT04408430",
      "title": "The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mitral Annular Calcification",
        "Mitral Stenosis",
        "Mitral Regurgitation",
        "Mitral Valve Disease"
      ],
      "interventions": [
        {
          "name": "Transseptal ViMAC",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Mayra Guerrero",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2021-03-08",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-13",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 16,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 12 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04408430"
    },
    {
      "nct_id": "NCT06894511",
      "title": "An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "AAA617",
          "type": "DRUG"
        },
        {
          "name": "ARPI: Abiraterone",
          "type": "DRUG"
        },
        {
          "name": "ARPI: Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "MALE",
        "summary": "18 Years to 100 Years · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2025-09-11",
      "completion_date": "2026-11-17",
      "has_results": false,
      "last_update_posted_date": "2026-11-12",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 5,
      "location_summary": "Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more",
      "locations": [
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06894511"
    },
    {
      "nct_id": "NCT02606045",
      "title": "Minimize Menorrhagia in Women With Von Willebrand Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Von Willebrand Diseases"
      ],
      "interventions": [
        {
          "name": "recombinant von Willebrand factor",
          "type": "DRUG"
        },
        {
          "name": "tranexamic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Margaret Ragni",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "13 Years to 45 Years · Female only"
      },
      "enrollment_count": 39,
      "start_date": "2019-02-07",
      "completion_date": "2022-08-30",
      "has_results": true,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 19,
      "location_summary": "Gilbert, Arizona • Orange, California • San Francisco, California + 16 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02606045"
    },
    {
      "nct_id": "NCT03574571",
      "title": "A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Docetaxel 75 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel 60 mg/m2",
          "type": "DRUG"
        },
        {
          "name": "Radium-223",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 732,
      "start_date": "2018-06-19",
      "completion_date": "2027-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 40,
      "location_summary": "Gilbert, Arizona • New Haven, Connecticut • Newark, Delaware + 32 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03574571"
    },
    {
      "nct_id": "NCT01479465",
      "title": "Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Simtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to match SIM",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 266,
      "start_date": "2011-12",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2019-04-17",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 56,
      "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479465"
    },
    {
      "nct_id": "NCT02912312",
      "title": "Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Invasive Breast Carcinoma",
        "Stage I Breast Cancer AJCC v7",
        "Stage IA Breast Cancer AJCC v7",
        "Stage IB Breast Cancer AJCC v7",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Hypofractionated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 805,
      "start_date": "2017-02-23",
      "completion_date": "2031-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-15",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 12,
      "location_summary": "Gilbert, Arizona • San Diego, California • Greeley, Colorado + 7 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Greeley",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02912312"
    },
    {
      "nct_id": "NCT01744665",
      "title": "A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CML"
      ],
      "interventions": [
        {
          "name": "nilotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2013-08-12",
      "completion_date": "2018-09-29",
      "has_results": true,
      "last_update_posted_date": "2020-03-10",
      "last_synced_at": "2026-11-21T01:41:08.128Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01744665"
    }
  ]
}